• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TRxADE HEALTH Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    9/24/24 4:05:38 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care
    Get the next $MEDS alert in real time by email
    false --12-31 0001382574 0001382574 2024-09-20 2024-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 20, 2024

     

    SCIENTURE HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-39199   46-3673928

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File No.)

     

    (I.R.S. Employer

    Identification No.)

     

    6308 Benjamin Rd, Suite 708

    Tampa, Florida 33634

    (Address of Principal Executive Offices)

     

    (866) 468-6535

    (Registrant’s Telephone Number)

     

    TRxADE HEALTH, Inc.

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.00001 per share   SCNX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws.

     

    On September 20, 2024, TRxADE HEALTH, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment to its Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to change the legal name of the Company from TRxADE HEALTH, Inc. to Scienture Holdings, Inc. (the “Name Change”). Other than the Name Change, there were no changes to the Company’s certificate of incorporation or bylaws. A copy of the Certificate of Amendment, as filed with the Secretary of State of the State of Delaware, is attached hereto as Exhibit 3.1, and incorporated herein by reference.

     

    Effective September 23, 2024, the Company’s common stock trades under the ticker symbol “SCNX”. The Name Change resulted in a change to the CUSIP number for the Company’s outstanding shares of common stock offered on the Nasdaq Stock Market LLC. The new CUSIP number for such common stock is 80880X104. Outstanding stock certificates for shares of the Company continue to be valid and need not be exchanged.

     

    Item 7.01. Regulation FD Disclosure.

     

    On September 20, 2024, and September 24, 2024, the Company and Scienture issued joint press releases announcing the Name Change. A copy of the press release dated September 20, 2024, is attached hereto as Exhibit 99.1 and is incorporated herein by reference. A copy of the press release dated September 24, 2024, is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

     

    The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    3.1   Certificate of Amendment of Second Amended and Restated Certificate of Incorporation.
         
    99.1   Joint Press Release, dated September 20, 2024.
         
    99.2   Joint Press Release, dated September 24, 2024.
         
    104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      SCIENTURE HOLDINGS, INC.
         
      By: /s/ Surendra Ajjarapu
        Surendra Ajjarapu
        Chief Executive Officer
         
    Date: September 24, 2024    

     

     

    Get the next $MEDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDS

    DatePrice TargetRatingAnalyst
    12/9/2021$4.50Buy
    EF Hutton
    More analyst ratings

    $MEDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on Trxade Health with a new price target

      EF Hutton initiated coverage of Trxade Health with a rating of Buy and set a new price target of $4.50

      12/9/21 9:10:50 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Maxim Group initiated coverage on Trxade Group

      Maxim Group initiated coverage of Trxade Group with a rating of Buy

      2/26/21 8:08:35 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Shankar Hariharan claimed ownership of 97,087 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:01 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • New insider Narasimhan Mani claimed ownership of 57,977 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:00 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Ajjarapu Surendra K was granted 10,000 shares (SEC Form 4) (Amendment)

      4/A - TRxADE HEALTH, INC (0001382574) (Issuer)

      5/28/24 5:01:21 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to "SCNX"

      TRxADE Health, Inc. today announced that it changed its name and ticker symbol to "Scienture Holdings, Inc." and "SCNX", respectively, and that the business will continue as a Nasdaq-listed company. TAMPA, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (the "Company") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of the Company, today announced that the Company has changed its name to "Scienture Holdings, Inc." Effective as of September 23, 2024, the Company's stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol "SCNX". Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions

      9/24/24 8:01:00 AM ET
      $MEDS
      $SCNX
      Other Pharmaceuticals
      Health Care
    • TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

      TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced that it is changing its name to Scienture Holdings, Inc. ("Scienture Holdings"), effective Monday, September 23, 2024. Scienture Holdings stock will begin trading under the new ticker symbol NASDAQ:SCNX on September 23, 2024. About TRxADE TRxADE HEALTH, INC. historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. Our current primary operations are conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC ("IPS"), whi

      9/20/24 11:59:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    SEC Filings

    See more
    • TRxADE HEALTH Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Scienture Holdings, Inc. (0001382574) (Filer)

      9/24/24 4:05:38 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form DEF 14C filed by TRxADE HEALTH Inc.

      DEF 14C - TRxADE HEALTH, INC (0001382574) (Filer)

      8/28/24 4:05:30 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form PRE 14C filed by TRxADE HEALTH Inc.

      PRE 14C - TRxADE HEALTH, INC (0001382574) (Filer)

      8/15/24 9:57:20 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Leadership Updates

    Live Leadership Updates

    See more

    $MEDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MEDS
    Financials

    Live finance-specific insights

    See more
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

      TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO of Scienture. Dr. Narasimhan Mani is an experienced healthcare professional and a proven leader with over 25 years of experience in both the scientific and business areas of the pharmaceutical industry. He currently is a part of the Executives-in-Residence program at New Rhein Hea

      8/5/24 8:01:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

      Forbes Fisher Appointed as Chief Operating Officer.Dr. Eugenio Bortone Appointed as Chief Innovation & Food Technology Officer. TAMPA, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc (NASDAQ:MEDS), parent company of pharmaceutical B2B exchange platform, which recently merged with Superlatus, Inc today announced the appointments of Forbes Fisher as Chief Operating Officer and Dr. Eugenio (Gino) Bortone as Chief Innovation & Food Technology Officer. Forbes brings over 25 years of Food Services industry experience and will lead product innovation and information technology, and drive sales and supply chain optimization to support growth and profitability initiatives. Dr. Eugenio

      8/3/23 9:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by TRxADE HEALTH Inc. (Amendment)

      SC 13G/A - TRxADE HEALTH, INC (0001382574) (Subject)

      2/14/24 2:50:57 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by TRxADE HEALTH Inc.

      SC 13G - TRxADE HEALTH, INC (0001382574) (Subject)

      2/14/23 1:05:54 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by TRxADE HEALTH Inc. (Amendment)

      SC 13D/A - TRxADE HEALTH, INC (0001382574) (Subject)

      10/19/22 4:30:15 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • TRxADE Health, Inc. Announces Special Cash Dividend

      TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, in

      7/9/24 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • TRxADE Health, Inc. Announces Special Cash Dividend

      TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on or about March 22, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, includi

      3/6/24 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

      Spero is another addition to the growing Superlatus CPG portfolio under their Urgent Company umbrella of brands.Spero® is a plant-based tech company specializing in alternative dairy and egg replacements, on a mission to outcompete traditional dairy and egg products in scale, price, taste, and nutrition by utilizing internationally patent-pending technologies that transforms low-cost, sustainable, and scalable ingredients into plant-based alternatives. Spero's mission is to scale mainstream dairy alternatives and have them be delicious, affordable, and available to everyone, everywhere. TAMPA, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. ("Superlatus"), wholly owned subsidary of

      10/4/23 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care